The chimeric antigen receptor T-cell (CAR-T) therapy field has delivered remarkable clinical proof-of-concept since the first FDA approvals in 2017, with numerous products demonstrating exceptional initial response rates in hematologic malignancies. Yet nearly a decade into the commercial era, the translation of compelling early efficacy into sustained commercial franchises has proven elusive for many programs. While Legend Biotech's CARVYKTI achieved approximately $963 million in net trade sales during fiscal year 2024 and treated over 5,000 patients—establishing it as the fastest-launching CAR-T in history14—this success contrasts sharply with the broader CAR-T landscape, where Gilead's Kite cell therapy revenue declined 7% from fiscal year 2024 to 2025 and is projected to fall another 10% in 202616. This divergence illustrates that early clinical efficacy, while necessary, is insufficient to guarantee durable commercial performance. The failure of many CAR-T programs to sustain market traction reflects an interconnected web of biological limitations, operational complexities, safety liabilities, reimbursement constraints, and competitive pressures that collectively erode the value proposition for patients, providers, and payers.
Biological Mechanisms Limiting Long-Term Durability
The primary biological barrier to CAR-T commercial durability is poor T-cell persistence following infusion. Clinical data from multiple myeloma studies reveal that engineered T cells remain detectable up to three months post-infusion in most patients, but only approximately 20% maintain detectable CAR-T cells at 12 months4. This short persistence window directly limits durable remission and increases relapse risk, undermining the premise of a one-time curative intervention that would justify premium pricing. The underlying mechanisms driving this poor persistence are multifactorial. Immunogenicity of CAR constructs, particularly those utilizing non-human single-chain variable fragments, induces anti-CAR antibody formation that accelerates T-cell clearance and constitutes a higher risk of relapse4. Efforts to develop humanized or fully human CAR designs represent attempts to address this limitation, but these next-generation constructs remain largely investigational.
Antigen escape and shedding represent the most common causes of CAR-T failure across multiple disease contexts4. In multiple myeloma, B-cell maturation antigen (BCMA)—the most successful CAR-T target—undergoes gamma-secretase-mediated shedding, producing soluble BCMA that may competitively interfere with CAR-T recognition. This mechanism drives development of dual-target approaches combining BCMA with CD19, SLAMF7, or CD38 to broaden antigen coverage and reduce escape risk, yet these strategies add manufacturing complexity and regulatory uncertainty. Beyond antigen shedding, the tumor microenvironment imposes critical barriers through PD-1/PD-L1-mediated T-cell exhaustion, regulatory T-cell accumulation, and myeloid-derived suppressor cell infiltration4. These immunosuppressive mechanisms limit CAR-T function even when cells persist, creating a durability ceiling independent of initial response rates.
The fitness and phenotype of infused T cells critically influence clinical outcomes. Prior chemotherapy and disease-related myelosuppression compromise T-cell fitness, with malignancy itself and chemotherapy-induced cytopenias hampering the functional capacity of collected lymphocytes4. Memory-like phenotypes, including naive and stem memory T cells, correlate with longer remission duration, driving manufacturing innovations toward memory enrichment strategies such as rapid manufacturing platforms (24 to 36 hours) and memory-enriched selection protocols. However, these manufacturing advances increase production costs and technical complexity, creating tension between biological optimization and commercial scalability.
Safety Liabilities and Site-of-Care Constraints
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) represent the primary safety liabilities constraining CAR-T commercial adoption6. CRS results from excessive cytokine release—including interleukin-2, interferon-gamma, tumor necrosis factor-alpha, interleukin-6, and granulocyte-macrophage colony-stimulating factor—following CAR-T activation, manifesting as fever and multi-organ dysfunction requiring intensive monitoring and tocilizumab or corticosteroid intervention. ICANS encompasses encephalopathy, seizures, cerebral edema, and movement disorders, with underlying mechanisms that remain poorly understood and treatment options limited to supportive care and corticosteroids6. These toxicities necessitate specialized hospitalization infrastructure, tocilizumab availability, intensive care unit-level monitoring, and trained multidisciplinary teams—requirements formalized through FDA Risk Evaluation and Mitigation Strategies programs12.
The REMS framework addresses serious risks of CRS and ICANS through healthcare system readiness and provider education requirements, creating structural constraints that directly impact accessibility and real-world implementation1. As CAR-T therapy expanded beyond academic medical centers to community oncology settings, limited experience in toxicity management became a critical barrier. The FDA modified REMS requirements in 2024 to minimize compliance burden on the healthcare delivery system, indicating regulatory recognition that existing frameworks were creating access barriers2. Nevertheless, site-of-care constraints remain substantial. Data from the competitive landscape analysis demonstrates that bispecific T-cell engagers and antibody-drug conjugates can be administered at community oncology centers without REMS certification, enabling broader patient access and reducing referral friction11. This operational disadvantage directly constrains CAR-T market penetration, as the majority of cancer care occurs in community settings rather than specialized centers.
Emerging long-term toxicities further constrain commercial viability. In calendar year 2024, the FDA Center for Biologics Evaluation and Research required a boxed warning for T-cell malignancies following treatment with BCMA-directed or CD19-directed autologous CAR-T immunotherapies—a secondary malignancy risk that emerged from post-market surveillance2. Prolonged cytopenias persisting months post-infusion, hypogammaglobulinemia requiring long-term immunoglobulin replacement, and potential on-target off-tumor toxicities such as BCMA crossing the blood-brain barrier to induce progressive neurocognitive disorders represent safety liabilities incompletely characterized during pivotal trials48. These late toxicities increase ongoing healthcare costs and reduce patient quality of life, eroding the value proposition relative to competing modalities with more predictable safety profiles.
Manufacturing and Operational Bottlenecks
Autologous CAR-T manufacturing requires three to four weeks from leukapheresis to infusion—a vein-to-vein time during which disease progression and bridging therapy toxicity may compromise patient fitness and product quality4. Poor T-cell fitness following multiple prior therapies directly reduces manufacturing success rates and product potency, with production failures occurring in heavily pretreated populations. This manufacturing delay creates a critical window for disease progression, particularly in aggressive malignancies, and necessitates bridging chemotherapy that may further deplete functional T cells. Real-world evidence studies examining CAR-T efficacy in patients previously treated with blinatumomab—a bispecific CD19/CD3 T-cell engager—illustrate this challenge, as prior T-cell activation and checkpoint upregulation in blinatumomab-exposed patients may compromise subsequent CAR-T manufacturing and clinical outcomes9.
Allogeneic CAR-T approaches aim to overcome manufacturing delays through pre-manufactured, off-the-shelf products derived from healthy donor T cells. Early clinical data from allogeneic BCMA CAR-T programs demonstrate 61.5% overall response rates with manageable toxicity profiles, including 52.4% CRS incidence without grade 4 to 5 events4. However, allogeneic approaches introduce new regulatory considerations around graft-versus-host disease risk requiring transcription activator-like effector nuclease or CRISPR-Cas9 gene editing to disrupt T-cell receptor genes57. These genetic modifications necessitate long-term follow-up for insertional mutagenesis and secondary malignancy risk, with FDA and European Medicines Agency guidelines establishing comprehensive surveillance frameworks including integration site analysis during long-term follow-up23. The regulatory complexity of gene-edited allogeneic products, combined with their early-stage clinical development, limits near-term competitive impact relative to established autologous CAR-T and approved bispecific alternatives.
Market Access and Reimbursement Complexity
Hospital economics for CAR-T therapies remain challenging despite Medicare payment increases. The Centers for Medicare and Medicaid Services finalized a 16.8% increase in the Medicare Severity Diagnosis Related Group 018 base rate for fiscal year 2026, raising reimbursement from $269,139 to $314,231, while reducing the fixed-loss outlier threshold from $46,147 to $40,39712. These changes modestly improve cost recovery, yet hospitals continue to face economic shortfalls where total costs exceed combined MS-DRG and outlier payments. Clinical trial cases face substantially lower reimbursement, with the clinical trial adjustment factor reduced from 0.33 to 0.16 and the clinical trial base rate declining 43.4% from $88,876 to $50,27712. This reimbursement gap creates friction in trial enrollment and may slow evidence generation for label expansions. The proposed shift to market-based rate-setting using median Medicare Advantage negotiated rates beginning in fiscal year 2029 introduces future uncertainty13, as divergence between fee-for-service methodology and MA contracted rates could substantially impact hospital willingness to maintain CAR-T programs.
New Technology Add-On Payments approved for lisocabtagene maraleucel in chronic lymphocytic leukemia and afamitresgene autoleucel in synovial sarcoma provide supplemental reimbursement up to $316,860 and $472,550 respectively12. However, the denial of NTAP for obexelimab in acute lymphoblastic leukemia due to substantial similarity to existing products signals increasing difficulty for new CAR-T entries to satisfy regulatory newness criteria as the market matures. Outside the United States, reimbursement dynamics vary substantially. European Union reference pricing systems create pricing pressure as national health technology assessment bodies demand cost-effectiveness evidence and outcomes-based agreements. China's volume-based procurement system and domestic manufacturing capacity favor locally developed CAR-T products, though the approval of imported bispecifics such as glofitamab indicates openness to international competition11.
Competitive Disruption from Off-the-Shelf Modalities
The most significant commercial threat to CAR-T durability derives from approved bispecific T-cell engagers that eliminate manufacturing delays and apheresis requirements. Epcoritamab, glofitamab, and odronextamab—CD20×CD3 bispecifics approved for diffuse large B-cell lymphoma in the United States and European Union—offer subcutaneous or intravenous administration without specialized infrastructure, enabling outpatient treatment and community oncology access11. These operational advantages directly address CAR-T limitations documented in regulatory frameworks, providing immediate product availability during the three-to-four-week window when autologous CAR-T patients face disease progression risk. Clinical development programs evaluating bispecifics in earlier lines of therapy threaten to preempt CAR-T positioning, as second-line bispecific use may deplete the population of CAR-T-eligible patients while potentially compromising T-cell fitness for subsequent CAR-T manufacturing in patients who progress.
Antibody-drug conjugates targeting CD19, CD79b, and other B-cell antigens represent a second competitive threat. Loncastuximab tesirine and polatuzumab vedotin—approved CD19-ADC and CD79b-ADC products—combine targeted delivery with established chemotherapy infrastructure, enabling standard oncology infusion without REMS certification or specialized monitoring11. Pipeline ADCs targeting ROR1, CD30, CD22, and CD37 demonstrate strategic diversification to address antigen heterogeneity through sequential or combination approaches rather than engineered multi-specificity. The ability to combine ADCs and bispecifics with checkpoint inhibitors or chemotherapy—not feasible with CAR-T due to lymphodepletion requirements—creates additional competitive advantages in earlier-line development and combination regimens.
Gilead Sciences' acquisition of Arcellx for $7.8 billion in February 2026 illustrates the competitive intensity in the multiple myeloma CAR-T space. Anito-cel demonstrated 97% overall response rates and 68% complete response rates in the pivotal iMMagine-1 Phase 2 study, with FDA biologics license application acceptance and a December 2026 action date16. This acquisition reflects recognition that sustaining CAR-T market position requires continuous pipeline replenishment, as existing products face durability challenges and competitive encroachment. Legend Biotech's CARVYKTI maintained dominant positioning with over 10,000 patients treated and $1.7 billion in 12-month net trade sales through the third quarter of 2025, supported by 279 global treatment sites across 14 countries16. However, even this market leader faces ongoing competitive pressure as bispecific and ADC alternatives demonstrate comparable or superior convenience profiles.
Regulatory and Long-Term Follow-Up Burdens
Post-marketing surveillance requirements impose ongoing costs and prescriber uncertainty. The FDA boxed warning for T-cell malignancies mandated in 2024 reflects secondary cancer risk that emerged only through long-term post-market surveillance of BCMA-directed and CD19-directed CAR-T recipients2. European Medicines Agency guidelines establish comprehensive long-term follow-up protocols addressing insertional mutagenesis risk, with requirements for potency testing, cell population characterization, and safety follow-up extending years beyond initial treatment3. These regulatory obligations increase development timelines and manufacturing costs while creating prescriber hesitancy regarding incompletely characterized late effects. The FDA's engagement with patients on gene therapy long-term follow-up requirements, including integration site analysis for integrating viral vectors, parallels CAR-T monitoring needs and signals continuing regulatory evolution2.
Data regarding late effects and long-term toxicities continue to evolve, with incomplete characterization of secondary malignancy risk requiring extended observation8. This uncertainty complicates patient counseling, informed consent processes, and shared decision-making, particularly when comparing CAR-T to bispecific or ADC alternatives with more mature safety databases. The 15-year follow-up requirements for gene therapy products utilizing integrating vectors create patient retention challenges and ongoing surveillance costs that extend far beyond initial commercial revenue recognition.
Mitigation Strategies and Future Outlook
The CAR-T field is pursuing multiple engineering and operational innovations to address identified limitations. Dual-target and multi-specific CAR constructs combining CD19 with CD20, BCMA with CD19, or BCMA with CD38 aim to prevent antigen escape, though these approaches remain largely in Phase 1 and Phase 2 development while competing modalities have achieved approval11. Armored CAR designs incorporating cytokine expression or checkpoint blockade attempt to overcome tumor microenvironment immunosuppression, while logic-gated and switchable CAR platforms offer enhanced control over T-cell activation and persistence. Rapid manufacturing platforms reducing vein-to-vein time to 24 to 36 hours and memory-enriched manufacturing protocols selecting for stem memory phenotypes represent operational strategies to improve product quality and reduce disease progression during production4.
Decentralized and point-of-care manufacturing models aim to overcome site-of-care constraints, though regulatory frameworks for distributed manufacturing remain under development. Closed automated manufacturing systems promise improved consistency and reduced contamination risk, potentially addressing comparability requirements that constrain manufacturing scale-up3. The global CAR-T market is projected to expand from $2.7 billion in 2025 to between $27.5 billion and $146.55 billion by 2033 to 2034, reflecting compound annual growth rates of 32% to 38% 171819. However, these projections assume sustained innovation in manufacturing, regulatory approval of next-generation constructs, and successful competition against bispecific and ADC alternatives.
Sustained commercial success will require differentiation through earlier-line positioning supported by head-to-head comparative efficacy data, demonstrable durability advantages over sequential therapy approaches, manufacturing innovations that reduce vein-to-vein time and cost structure, and safety profiles that enable broader site-of-care access. The divergent trajectories of CARVYKTI—achieving rapid market penetration through operational excellence and favorable clinical profile—versus declining revenues for earlier CAR-T products illustrate that biological efficacy alone is insufficient. Success demands cross-functional integration of clinical differentiation, manufacturing scalability, regulatory navigation, reimbursement optimization, and competitive positioning within rapidly evolving treatment paradigms where off-the-shelf alternatives increasingly challenge the autologous CAR-T value proposition.